Immune-mediated thrombotic thrombocytopenic purpura in childhood treated by caplacizumab, about 3 cases

被引：0

作者：

Julie Boudali

Benjamin Hallak

Marie Haeck

Anne-Laure Sellier-Leclerc

Marc Ulrich

Paul Coppo

Stéphanie Tellier

François Provôt

机构：

[1] CHRU Lille,Department of Nephrology

[2] CHU Toulouse,Department of Pediatric Nephrology and Rheumatolgy, French Reference Center of Rare Renal Diseases (SORARE)

[3] CHG Valenciennes,Department of Nephrology

[4] Hôpital Femme Mère Enfant,Department of Pediatric Nephrology

[5] Hôpital Saint Antoine,French Reference Center for Thrombotic Microangiopathies

[6] AP-HP,undefined

来源：

Journal of Nephrology | 2022年 / 35卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunately, this treatment is restricted to adults. We report our experience in three children who were treated successfully with caplacizumab.

引用

页码：653 / 656

页数：3

共 26 条

[1]

Joly BS(2017)Thrombotic thrombocytopenic purpura Blood 129 2836-2846

[2]

Coppo P(2019)An update on pathogenesis and diagnosis of thrombotic thrombocytopenic purpura Expert Rev Hematol 12 383-395

[3]

Veyradier A(2019)Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine Res Pract Thromb Haemost 3 26-37

[4]

Joly BS(2016)Caplacizumab for acquired thrombotic thrombocytopenic purpura N Engl J Med 374 511-522

[5]

Coppo P(2019)Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura N Engl J Med 380 335-346

[6]

Veyradier A(2019)Use of caplacizumab in a child with refractory thrombotic thrombocytopenic purpura Pediatr Blood Cancer 66 e27737-1628

[7]

Coppo P(2021)Refractory acquired thrombotic thrombocytopenic purpura treated with caplacizumab in a pediatric patient with systemic lupus erythematosus Pediatr Blood Cancer 68 e28534-327

[8]

Cuker A(2019)Caplacizumab for relapsing thrombotic thrombocytopenic purpura Pediatr Nephrol Berl Ger 34 1625-e546

[9]

George JN(2019)Therapeutic plasma exchange in thrombotic thrombocytopenic purpura Presse Medicale Paris Fr 1983 319-434

[10]

Peyvandi F(2016)Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy Lancet Haematol 3 e537-undefined

← 1 2 3 →